Article
Hey, biopharma: JPM isn't the be-all, end-all for dealmaking, Sanofi exec says
Rating:
0.0
Views:
101
Likes:
1
Library:
1
Among the many things we took for granted before COVID-19 were in-person gatherings, where everyone in biopharma could catch up, talk shop and maybe emerge with a new partner or two. Sanofi isn't sweating it, though—the sudden need to go virtual gave companies a chance to get out of their dealmaking comfort zone.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value